Katherine Sprugel, PhD, BS

Dr. Sprugel is a toxicologist with over 30 years of experience in drug development at local biotechnology companies, including ZymoGenetics, PathoGenesis, Chiron, and Amgen. She has extensive experience in nonclinical efficacy and safety evaluations, ranging from lead identification to international marketing authorizations and pharmacovigilance support. Her core expertise is safety assessment and nonclinical development strategy for monoclonal antibodies and engineered proteins, but she has also worked on small molecules, inhalation delivery and drug-device combinations.